Publication details
Mitoxantrone therapy in rapidly worsening multiple sclerosis
| Authors | |
|---|---|
| Year of publication | 2005 |
| Type | Article in Periodical |
| Magazine / Source | Bratislavské lekárske listy |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | multiple sclerosis; immunotherapy; mitoxantrone; EDSS |
| Description | The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evaluated. Nonparametric Wilcoxon matched pair test was used for statistical analysis. |
| Related projects: |